A New Mechanism Linking Lipid and Altered Inflammation in Neovascular AMD
Jing Chen, PhD
Boston Children's Hospital (Boston, MA)
July 1, 2013 to June 30, 2015
Grant Reference ID:
Control of Neovascular AMD by Nuclear Receptor RORalpha
A major cause of blindness in AMD is abnormal blood vessel growth in the back of the eye (choroidal neovascularization), the “wet” form of AMD. The proposed work will help define a novel pathway linking dysregulation of lipid homeostasis (fat levels) with altered inflammatory responses in AMD. Both processes are fundamentally important to the development and progression of wet AMD. Dr. Chen’s discoveries may help to develop a new way to treat AMD by specifically changing the levels of a lipid sensing nuclear receptor protein that modifies inflammation.
In preliminary studies, Dr. Chen and her collaborators linked the presence of significant genetic changes to the nuclear receptor, RORalpha (retinoic-acid-receptor-related orphan receptor alpha), with the risk of developing wet AMD. However, it is not known if RORalpha contributes to the progression of wet AMD. In this project, Dr. Chen’s team will determine whether RORalpha, as a sensor of lipid homeostasis, influences the development of wet AMD by causing changes in tissue inflammation. The analysis will be done with both genetic (DNA) and pharmacologic (small molecule drug) approaches to modulate RORalpha activity in animal models of AMD.
AMD is a complex disease linked to problems with lipid metabolism, and inflammation/immune functions. A more integrated treatment approach that corrects more than one of the mechanisms that can lead to AMD, such as problems with inflammation and lipid metabolism, would be of great benefit. When this study is complete, it will identify a novel control mechanism in wet AMD that links two major pathways contributing to AMD, and provide clues to a new therapeutic approach to treat this blinding eye disease.
About the Researcher
Dr. Chen is an Assistant Professor of Ophthalmology at Boston Children’s Hospital. She received her Ph.D. degree from Boston University and completed her postdoctoral training at Boston Children’s Hospital. Dr. Chen’s work focuses on understanding the causes and identifying potential therapies to treat pathologic blood vessel growth in vascular eye diseases, including the wet form of age-related macular degeneration.
First published on: Monday, July 1, 2013
Last modified on: Thursday, June 27, 2013